Clinical Trials on Primary Immunodeficiency Diseases (PID)

Total 54454 results

VA Office of Research and Development

Completed

Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH) (MESH)

Smoking | Human Immunodeficiency Virus

United States
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency

Japan
CSL Behring

Completed

Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

Primary Immune Deficiency

United States
CSL Limited

Completed

Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency

Primary Immune Deficiency

Australia, New Zealand
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Mahidol University
Ministry of Health, Thailand

Unknown

Treatment of Adult-Onset Immunodeficiency With Bortezomib

Adult-onset Immunodeficiency

Thailand
University Hospital, Caen

Completed

Intensive Care Unit and Secondary and Primary Immune Deficiency (ICUSPID)

Primary Immune Deficiency Disorder

France
RetroLead (Shanghai) BioPharma Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects

Human Immunodeficiency Virus-1 (HIV-1) Infection
ViiV Healthcare
GlaxoSmithKline

Completed

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

Infection, Human Immunodeficiency Virus

United States
Janssen Infectious Diseases BVBA

Completed

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

Human Immunodeficiency Virus Type 1

Belgium
ViiV Healthcare
GlaxoSmithKline

Terminated

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Infection, Human Immunodeficiency Virus I

United States, Canada, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)

Infection, Human Immunodeficiency Virus

Germany
ViiV Healthcare
GlaxoSmithKline

Completed

ZIAGEN® Post-marketing Surveillance

Infection, Human Immunodeficiency Virus I

Korea, Republic of
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
AbbVie (prior sponsor, Abbott)

Completed

Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program

Human Immunodeficiency Virus Infection
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

GSK1349572 Drug Interaction Study With Efavirenz

Infections, Human Immunodeficiency Virus and Herpesviridae

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Drug-drug Interaction (DDI) Rifabutin

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet

Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

Relative Bioavailability Study With BMS-955176

Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

GSK706769 Repeat Dose Study

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

Infection, Human Immunodeficiency Virus

United States
Janssen-Cilag G.m.b.H

Completed

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (PEPDar)

Human Immunodeficiency Virus (HIV)

Germany
ViiV Healthcare
GlaxoSmithKline

Completed

PENTA Fosamprenavir Study

Infection, Human Immunodeficiency Virus
ViiV Healthcare

Completed

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Food Effect Study With BMS-955176

Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Infection, Human Immunodeficiency Virus I

United States, Spain, Canada, Russian Federation, Romania, Belgium, South Africa
ViiV Healthcare
GlaxoSmithKline

Completed

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

Infections, Human Immunodeficiency Virus and Herpesviridae

United States
ViiV Healthcare
Glaxosmithkline/Quintiles

Completed

A Study to Evaluate the Effect of High Fat Meal on Cabotegravir

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Infection, Human Immunodeficiency Virus

United States, Canada, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

Fosamprenavir Expanded Access

Infection, Human Immunodeficiency Virus

Switzerland
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Abivax S.A.

Completed

Safety, PK and PD Study of ABX464 in Untreated HIV Patients

Human Immunodeficiency Virus Infections

Thailand, Mauritius
ViiV Healthcare
Pfizer

Withdrawn

Maraviroc Compassionate Use

Human Immunodeficiency Virus Type 1
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. (VIKING-3)

Infection, Human Immunodeficiency Virus

United States, Spain, France, Canada, Portugal, Italy, Belgium
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

Infection, Human Immunodeficiency Virus

United States
Bristol-Myers Squibb

Completed

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat (Atazanavir)

Human Immunodeficiency Virus Type 1 (HIV-1)

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects

Infections, Human Immunodeficiency Virus and Herpesviridae
GlaxoSmithKline

Completed

Fosamprenavir in Pts With Hepatic Impairment

Infection, Human Immunodeficiency Virus
Bristol-Myers Squibb

Completed

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

HIV Infections | Human Immunodeficiency Virus Type 1 (HIV-1)

United States, Netherlands
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Drug Interaction Study Between Dolutegravir and Prednisone

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

DDI Study of Etravirine and GSK1265744

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States

Clinical Trials on Primary Immunodeficiency Diseases (PID)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations